Thrombopoietin receptor agonists protect human cardiac myocytes from injury by activation of cell survival pathways

Journal of Pharmacology and Experimental Therapeutics

Volumn 352, Issue 3, 2015, Pages 429-437

  Baker, John E ^a   Su, Jidong ^a   Koprowski, Stacy ^a   Dhanasekaran, Anuradha ^b   Aufderheide, Tom P ^a   Gross, Garrett J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b ANNA UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ELTROMBOPAG; JANUS KINASE 2; PROTEIN TYROSINE KINASE; THROMBOPOIETIN; BENZOIC ACID DERIVATIVE; CARDIOTONIC AGENT; HYDRAZINE DERIVATIVE; MPL PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; THROMBOPOIETIN RECEPTOR;

ADULT; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL DAMAGE; CELL HYPOXIA; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; REOXYGENATION; WESTERN BLOTTING; AGONISTS; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

BENZOATES; CARDIOTONIC AGENTS; CELL HYPOXIA; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDRAZINES; MYOCYTES, CARDIAC; PYRAZOLES; RECEPTORS, THROMBOPOIETIN; SIGNAL TRANSDUCTION; THROMBOPOIETIN;

EID: 84921466193     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.221747     Document Type: Article

References (18)

1. Abbott C, Huang G, Ellison AR, Chen C, Arora T, Szilvassy SJ, and Wei P (2010) Mouse monoclonal antibodies against human c-Mpl and characterization for flow cytometry applications. Hybridoma (Larchmt) 29:103-113.
2. Baker JE, Su J, Hsu A, Shi Y, Zhao M, Strande JL, Fu X, Xu H, Eis A, Komorowski R, et al. (2008) Human thrombopoietin reduces myocardial infarct size, apoptosis, and stunning following ischaemia/reperfusion in rats. Cardiovasc Res 77:44-53.
3. Brar BK, Stephanou A, Knight R, and Latchman DS (2002) Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. J Mol Cell Cardiol 34:483-492.
4. Carroll R and Yellon DM (2000) Delayed cardioprotection in a human cardiomyocytederived cell line: the role of adenosine, p38MAP kinase and mitochondrial KATP. Basic Res Cardiol 95:243-249.
5. Chung J, Uchida E, Grammer TC, and Blenis J (1997) STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 17:6508-6516.
6. Coers J, Ranft C, and Skoda RC (2004) A truncated isoform of c-Mpl with an essential C-terminal peptide targets the full-length receptor for degradation. J Biol Chem 279:36397-36404.
7. Decker T and Kovarik P (2000) Serine phosphorylation of STATs. Oncogene 19: 2628-2637.
8. Dhanasekaran A, Gruenloh SK, Buonaccorsi JN, Zhang R, Gross GJ, Falck JR, Patel PK, Jacobs ER, andMedhoraM (2008) Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am J Physiol Heart Circ Physiol 294:H724-H735.
9. El Jamali A, Freund C, Rechner C, Scheidereit C, Dietz R, and Bergmann MW (2004) Reoxygenation after severe hypoxia induces cardiomyocyte hypertrophy in vitro: activation of CREB downstream of GSK3beta. FASEB J 18:1096-1098.
10. Erhardt JA, Erickson-Miller CL, Aivado M, Abboud M, Pillarisetti K, and Toomey JR (2009) Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol 37: 1030-1037.
11. Erickson-Miller CL, Delorme E, Tian SS, Hopson CB, Landis AJ, Valoret EI, Sellers TS, Rosen J, Miller SG, Luengo JI, et al. (2009) Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 27: 424-430.
12. Germack R and Dickenson JM (2005) Adenosine triggers preconditioning through MEK/ERK1/2 signalling pathway during hypoxia/reoxygenation in neonatal rat cardiomyocytes. J Mol Cell Cardiol 39:429-442.
13. Kiladjian JJ, Elkassar N, Hetet G, Briere J, Grandchamp B, and Gardin C (1997) Study of the thrombopoitin receptor in essential thrombocythemia. Leukemia 11: 1821-1826.
14. Li J, Sabath DF, and Kuter DJ (2000) Cloning and functional characterization of a novel c-mpl variant expressed in human CD34 cells and platelets. Cytokine 12: 835-844.
15. Vigon I, Mornon JP, Cocault L, Mitjavila MT, Tambourin P, Gisselbrecht S, and Souyri M (1992) Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 89:5640-5644.
16. Wierenga AT, Vogelzang I, Eggen BJ, and Vellenga E (2003) Erythropoietin-induced serine 727 phosphorylation of STAT3 in erythroid cells is mediated by a MEK-, ERK-, and MSK1-dependent pathway. Exp Hematol 31:398-405.
17. Zhang DM, Chai Y, Erickson JR, Brown JH, Bers DM, and Lin YF (2014) Intracellular signalling mechanism responsible for modulation of sarcolemmal ATP-sensitive potassium channels by nitric oxide in ventricular cardiomyocytes. J Physiol 592:971-990.
18. Zhou J, Li J, Rosenbaum DM, and Barone FC (2011) Thrombopoietin protects the brain and improves sensorimotor functions: reduction of stroke-induced MMP-9 upregulation and blood-brain barrier injury. J Cereb Blood Flow Metab 31:924-933.